KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab plus lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).

被引：0
|
作者：
Kramer, Gero
Shore, Neal D.
Joshua, Anthony M.
Li, Xin Tong
Poehlein, Christian Heinrich
Schloss, Charles
De Bono, Johann S.
Yu, Evan Y.
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[3] St Vincents Hosp Sydney, Sydney, NSW, Australia
[4] Merck & Co Inc, Kenilworth, NJ USA
[5] Royal Marsden NHS Fdn Trust, London, England
[6] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.TPS215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS215
引用
收藏
页数：3
相关论文
共 50 条
  • [1] PEMBROLIZUMAB plus LENVATINIB IN PATIENTS WITH ADENOCARCINOMA METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) OR TREATMENT-EMERGENT NEUROENDOCRINE MCRPC: PHASE 1B/2 KEYNOTE-365 COHORTS E/F
    Kramer, Gero
    Shore, Neal
    Joshua, Anthony
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A449 - A449
  • [2] KEYNOTE-365 cohorts G and H: Phase 1b/2 study of pembrolizumab plus vibostolimab combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).
    Shore, Neal D.
    De Bono, Johann S.
    Kramer, Gero
    Joshua, Anthony M.
    Li, Xin Tong
    Poehlein, Christian Heinrich
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [3] Phase Ib/II trial of pembrolizumab (pembro) plus lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F
    Kramer, G.
    Shore, N. D.
    Joshua, A. M.
    Li, X. T.
    Poehlein, C. H.
    Schloss, C.
    de Bono, J. S.
    Yu, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S669 - S670
  • [4] PEMBROLIZUMAB plus VIBOSTOLIMAB IN PATIENTS WITH ADENOCARCINOMA METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) OR TREATMENT-EMERGENT NEUROENDOCRINE MCRPC: PHASE 1B/2 KEYNOTE-365 COHORTS G/H
    Shore, Neal
    De Bono, Johann
    Kramer, Gero
    Joshua, Anthony
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A455 - A455
  • [5] Phase Ib/II trial of pembrolizumab (pembro) plus vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H
    de Bono, J. S.
    Shore, N. D.
    Kramer, G.
    Joshua, A. M.
    Li, X. T.
    Poehlein, C. H.
    Schloss, C.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S670 - S671
  • [6] Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).
    Yu, Evan Y.
    Wu, Haiyan
    Schloss, Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Pembrolizumab Combination Therapies in Patients With Metastatic Castration-Resistant Prostate Cancer: Cohorts A-C of the Phase 1b/2 KEYNOTE-365 Study
    Joshua, Anthony M.
    Gurney, Howard
    Retz, Margitta
    Tafreshi, Ali
    Fong, Peter
    Shore, Neal
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Berry, William R.
    Kolinsky, Michael Paul
    Sridhar, Srikala S.
    Conter, Henry Joacob
    Todenhofer, Tilman
    Appleman, Leonard J.
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    de Bono, Johann S.
    Yu, Evan Y.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 46 - 47
  • [8] Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study
    Joshua, A. M.
    Gurney, H.
    Retz, M.
    Tafreshi, A.
    Fong, P. C. C.
    Shore, N. D.
    Romano, E.
    Augustin, M.
    Piulats, J. M.
    Berry, W. R.
    Kolinsky, M. P.
    Sridhar, S. S.
    Conter, H. J.
    Todenhoefer, T.
    Appleman, L. J.
    Wu, H.
    Schloss, C.
    Poehlein, C. H.
    de Bono, J. S.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1325 - S1325
  • [9] Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.
    Augustin, Marinela
    Laguerre, Brigitte
    Baldini, Capucine
    Zedan, Ahmed H.
    Gonzalez-Billalabeitia, Enrique
    Fong, Peter C. C.
    Zukov, Ruslan
    Hammerer, Peter
    Prentice, Mark
    Shore, Neal D.
    Necchi, Andrea
    Todenhoefer, Tilman
    Kessler, Elizabeth R.
    Kose, Fatih
    Gurney, Howard
    Valderrama, Begona Perez
    Zhu, Pengfei
    Imai, Kentaro
    Liu, Yingjie
    McDermott, Raymond S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 148 - 148
  • [10] Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.
    Yu, Evan Y.
    Joshua, Anthony M.
    Shore, Neal D.
    Kramer, Gero
    Hu, Haixia
    Poehlein, Christian Heinrich
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS250 - TPS250
12345